In a report released this morning, Roth Capital analyst Joseph Pantginis reinitiated coverage on BioLineRx Ltd. (BLRX) with a Buy rating and an $8.
In a research note released Tuesday, Roth Capital analyst Scott Henry maintained a Buy rating on ANI Pharmaceuticals (ANIP) and raised his price target to $40.00 (from $38.
In a research note released Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals, Inc. (REGN) and a price target of $382.
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Palatin Technologies Inc. (PTN) and a price target of $6.
In a research report released today, Roth Capital analyst Ed Arce raised his price target on Durata Therapeutics (DRTX) to $28 (from $24), while maintaining a Buy rating on the stock. The new price target …
In a research note issued today, Roth Capital analyst Dave King raised his price target on Plantronics, Inc. (PLT) from $52.
In a research report released this morning, Roth Capital analyst Anton Brenner reiterated coverage with a “Buy” rating on Krispy Kreme Doughnuts (KKD), and a price target of $27.00 following an …
In a research note released Tuesday, Roth Capital analyst Scott Henry maintained a Buy rating on Salix Pharmaceuticals (SLXP), and a 12 month price target of $130/share, following today’s news that SLXP’s Xifaxan …
In a research note released today, Roth Capital analyst Scott Henry maintained a Buy rating with a $20 price target following Flamel Technologies’ (FLML) the FDA …
In a research note issued Friday, Roth Capital analyst Michael Staiger initiated a coverage on shares of Dot Hill Systems Corporation (HILL). He …
